Dr. Malhotra is the Director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, NY, Professor at the Department of Molecular Medicine and the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, NY, and a professor at the Feinstein Institutes for Medical Research in Manhasset, NY. Dr. Malhotra completed his undergraduate studies at Cornell University in 1985 and received his MD from Wake Forest University in 1989. After residency training in psychiatry at Georgetown University, he completed a research fellowship at the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH), where he initiated a research program in pharmacogenetics. Following his tenure at NIMH, Dr. Malhotra moved to the Zucker Hillside Hospital and developed an internationally recognized molecular genetics program focused on the major neuropsychiatric disorders.
Dr. Malhotra is principal investigator of grants from the National Institute of Mental Health (NIMH), NARSAD, and industry. He is a frequent speaker at international and national meetings, as well as giving numerous Grand Rounds presentations at academic institutions across the U.S. He is a member of Editorial Boards of several medical and scientific journals, participates in NIH study sections, and serves as the program chair for the only annual meeting dedicated to pharmacogenetics in psychiatry.
For decades, scientists at Zucker Hillside Hospital have been exploring every possible avenue to determine what causes schizophrenia and to test ways to treat the symptoms that alter the lives of one in every 100 people and their families.
Dr. Malhotra’s research group focuses on identifying the biological underpinnings of schizophrenia and is trying to determine how anti-psychotic drugs work to quell the symptoms of the disease. His group has identified a number of genes associated with increased risk for the disorder, determined their relationship with important clinical manifestations of illness, including cognitive impairment, and examined the role of genetic factors in predicting individual responses to pharmacological treatment.
Dr. Malhotra’s research group published the first genome-wide association study (GWAS) of schizophrenia, as well as developed a new analytic strategy to assess these data. Moreover, a recent project provides new evidence for a role of specific genetic factors in vulnerability to antipsychotic drug-induced weight gain, a common yet potentially serious side effect of treatment.
John M. Kane, M.D.
Miklos Argyelan, M.D.
Michael Birnbaum, M.D.
Barbara Cornblatt, Ph.D.
Christoph Correll, M.D.
Kristina Deligiannidis, M.D.
Pamela DeRosse, Ph.D.
Todd Lencz, Ph.D.
Georgios Petrides, M.D.
Delbert Robinson, M.D.
Jose Rubio-Lorente, M.D.
Anna Van Meter, Ph.D.
Jianping Zhang, M.D., Ph.D.
Cornell University, Ithaca, NY
Field of study: Pre-med
Bowman Gray School of Medicine, Winston-Salem, NC
Field of study: Medicine
Georgetown University Hospital, Washington, D.C.
Field of study: Psychiatric Resident
National Institute of Mental Health, NIH, MD
Degree: Need degree here
Field of study: Clinical Associate